aTYR PHARMA (ATYR) FCF Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly FCF Margin came in at 10796.32% in Q3 2025, down 13.28% quarter-over-quarter from 9530.64% in Q1 2024.

Analysis

aTYR PHARMA (ATYR) FCF Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported FCF Margin for 6 consecutive years, with 10796.32% the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, FCF Margin changed N/A year-over-year to 10796.32%; the trailing twelve-month figure through Mar 2026 stood at 31209.47% (changed N/A YoY), and the FY2025 full-year result was 32664.74%, down 322474.0% from the prior year.
FCF Margin retreated to 10796.32% in Q3 2025 per ATYR's latest filing, from 9530.64% in the prior quarter.
Across five years, FCF Margin topped out at 110.61% in Q4 2022 and bottomed at 10796.32% in Q3 2025.
Historically, FCF Margin has averaged 5825.82% across 4 years, with a median of 6198.18% in 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	34.70%
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	44.00%
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	30.39%
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	13.35%
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	-388.28%
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	-
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	22.62%
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	14.91%
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	-18,629.40%
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-	-

Historic Data

Download Data